ClinicalTrials.gg
RecruitingNCT04240834LD-ASPIRINUpdated Jun 18, 2024

Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention

A Phase 4 interventional study of Aspirin and Ticagrelor in Acute Coronary Syndrome and Interventional Cardiology, sponsored by Fu Wai Hospital, Beijing, China. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-18.

Sponsored by Fu Wai Hospital, Beijing, China · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing aspirin in Acute Coronary Syndrome — 7 open to participants now, 8 under way, 1 of them phase 3. Aspirin · Acute Coronary Syndrome.

Planned enrollment
9th of 26
1,220 · median 200
Started
2021
with 2 others
Phase 4
17 of 26
4 open now
Registered
15th of 26
by date
Lead sponsor
1 of 26
Fu Wai Hospital, Beijing, China

Among the 26 studies testing aspirin in Acute Coronary Syndrome, this one is the 9th largest by planned enrollment, is one of 3 that started in 2021, is one of 17 in phase 4, and was the 15th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

7 of the 26 studies testing aspirin in Acute Coronary Syndrome are open now, in 8 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing aspirin in Acute Coronary Syndrome, or all of them as a file.
02

Study summary

The present study is aimed to compare the safety and efficacy of Ticagrelor with low-dose Aspirin versus standard dual anti-platelet therapy (DAPT) in patients with acute coronary syndrome (ACS) at high risk for ischemic events after percutaneous coronary intervention (PCI) and stent implantation.

Read the detailed description

This is a prospective, randomized, open-label, blinded-endpoint evaluation, single-center Study. There will be 1220 ACS patients at high risk for ischemic events after successful PCI with implantation of at least one drug eluting stent who will be enrolled in Fuwai Hospital, China. Then those included subjects will be randomized to either Ticagrelor plus low-dose Aspirin (50mg daily, LD group) or Ticagrelor plus regular dose Aspirin (75mg daily, control group) for 12 months. The primary endpoint of the current study is to determine the impact of low-dose Aspirin plus Ticagrelor versus standard DAPT for 12 months on major adverse cardiac and cerebral events (MACCEs), and the secondary endpoint is to determine whether the protocol of low dose Aspirin plus Ticagrelor reduces bleeding events, sufficiently inhibits platelet function, and increases the medication adherence among the included patients. In summary, the present study is to provide new evidence and strategy about the anti-platelet protocol for ACS patients at high risk for ischemia.

03

Conditions studied

  • Acute Coronary Syndrome
  • Interventional Cardiology

Keywords

  • ACS
  • PCI
  • DAPI
  • Aspirin
  • Ticagrelor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ACS patients at high risk for ischemic events after successful PCI with implantation of at least one drug eluting stent
  • Able and willing to provide and participate in 12 months follow-up period
  • Able to receive DAPT treatment
  • Enrollment into the study will require meeting at least one angiographic or clinical inclusion and none of the exclusion criteria.

Clinical inclusion criteria:

  1. Family history of premature coronary heart disease (Coronary heart disease in first-degree male relative \<55 years old or in first-degree female relative \<65 years old)
  2. Repeated myocardial infarction
  3. Positive serum cardiac troponin I/T
  4. Combined with at least one organ/system with atherosclerotic disease (e.g. intracranial or peripheral arteries)
  5. Type 2 diabetes mellitus under medication
  6. Chronic kidney disease (\<60 mL/min/1.73 m2 or \<60ml/min)

Angiographic Inclusion Criteria:

  1. LM lesion requiring stents
  2. Proximal LAD lesion(s) requiring stents
  3. Bypass grafts lesion(s) requiring stents
  4. Overall stent length ≥60 mm
  5. History of in-stent thrombosis
  6. Bifurcation lesions requiring at least 2 stents
  7. Over two vessels lesions requiring stents
  8. Calcified target lesion(s) requiring atherectomy
  9. The intraoperative occurrence of no-reflow or slow-flow
  10. Compressed branch vessels with a diameter of at least 2.0 mm failing to reach flow restoration (at least TIMI 3)

Exclusion criteria

Exclusion Criteria:

  • Need for chronic oral anticoagulation
  • With cardiomyopathy(HCM/DCM/RCM)
  • With severe ventricular arrhythmia requiring ICD implantation
  • With chronic respiratory disease (, asthma, chronic bronchitis, pulmonary heart disease)
  • With severe infectious disease(active , active , AIDS)
  • With hematological disorders(thrombocytopenia, severe anemia, leukaemia)
  • With severe liver disease or kidney failure
  • With malignant tumor
  • With cognitive impairment
  • Unable or unwilling to provide or undergo follow-up
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,220 participants (estimated)

Study arms

  • Experimental
    LD group

    Low-dose Aspirin(50mg qd) + Ticagrelor( 90mg bid) for 12 months

    Drug: Aspirin · Drug: Ticagrelor

  • Active comparator
    Control group

    Regular Aspirin(75mg qd) + Ticagrelor(90mg bid) for 12 months

    Drug: Aspirin · Drug: Ticagrelor

Interventions

  • Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)

    Also known as: Acetylsalicylic Acid

  • Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)

    Also known as: Brilinta/Brilique

06

What researchers measure

Primary outcomes

  1. Major adverse cardiac and cerebral events (MACCEs)

    Number of participants with a composite of all-cause mortality, non-fatal myocardial infarction, non-fatal stroke or urgent target vessel revascularization

    Time frame: 12 months after randomization

Secondary outcomes

  1. Bleeding episode (Key secondary endpoint)

    Number of participants with major bleeding(Bleeding Academic Research Consortium (BARC) types ≥3) and/or minor bleeding(Bleeding Academic Research Consortium (BARC) types 0-2)

    Time frame: 12 months after randomization

  2. Platelet function

    Platelet inhibition, blood level and urine level of thromboxaneB2(TXB2)

    Time frame: 12 months after randomization

  3. Medication adherence

    Time frame: 12 months after randomization

  4. Bleeding-related withdrawal

    Time frame: 12 months after randomization

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Dec 2025, 58 months after the start.

Of 85 non-industry phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 58 months is above that.

Counting every sponsor, half of 92 studies reached it within 42 months; a quarter within 26 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2020
First posted
Jan 27, 2020
StartActual
Feb 1, 2021
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2026
Last update
Jun 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04240834
Lead sponsor
Fu Wai Hospital, Beijing, China
Responsible party
Qian Haiyan (MD, PhD, Fu Wai Hospital, Beijing, China) — Principal investigator
First posted
Jan 27, 2020
Start date
Feb 1, 2021
Primary completion
Dec 2025 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 18, 2024

Study contacts

Haiyan Qian, MD, PhD
Contact
ahqhy712@163.com
+8613811386143
Zhiyao Wei
Contact
weizhiyaoyx@163.com
+8615521192379
Haiyan Qian, MD, PhD
principal investigator · Fuwai Hospital, Beijing, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aspirin · Ticagrelor

Start the discussion